(Bloomberg) — Moderna Inc. is on its longest losing streak in more than two years, extending its slump from a record high in August to more than 50%.
The slide has wiped about $98 billion off the company’s market value since that peak. While the omicron variant is sweeping the world, Moderna’s shares were pressured as coronavirus pills by Pfizer Inc. and Merck & Co., Inc. recently received authorization from the FDA.
The shares were down 2.8% at $239.90 as of 12:50 p.m. in New York. They have fallen about 19% over the past six days, erasing almost $23 billion in market value.
To be sure, shares of the Cambridge, Massachusetts-based company are still up 136% on the year through Monday’s close. Moderna, which joined the S&P 500 in July, is one of the index’s top performers this year and lags only Tesla Inc. over the past two years.
Fellow Covid-19 vaccine maker Pfizer Inc. also slipped Tuesday, extending declines from its record high close on Dec. 16. BioNTech SE is on track for its longest losing streak since September 2020.
More stories like this are available on bloomberg.com
©2021 Bloomberg L.P.
